Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × SCLC × apatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 42 Carcinoma, Hepatocellular 39 Carcinoma, Non-Small-Cell Lung 15 Colorectal Neoplasms 12 Small Cell Lung Carcinoma 11 Ovarian Neoplasms 11 Nasopharyngeal Carcinoma 11 Breast Neoplasms 11 Sarcoma 10 Cholangiocarcinoma 10 Triple Negative Breast Neoplasms 9 Lung Neoplasms 9 Esophageal Squamous Cell Carcinoma 9 Esophageal Neoplasms 9 Osteosarcoma 7 Advanced Gastric Cancer 7 Neoplasms 6 Head and Neck Neoplasms 6 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Recurrence 5 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Liver Neoplasms 5 Uterine Cervical Neoplasms 4 Glioma 4 Thyroid Neoplasms 3 Melanoma 3 Gastrointestinal Neoplasms 3 Drug-Related Side Effects and Adverse Reactions 3

Interventions

pembrolizumab 1 olaparib 1 ceralasertib 1 apatinib 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Tang-Du Hospital

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡